Navigation Links
Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
Date:5/18/2010

EOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented in "Clinical Cancer Research" with respect to REOLYSIN, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
2. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
3. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
4. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
5. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
6. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
7. Oncolytics Biotech(R) Inc. Announces Unit Offering
8. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
9. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
10. Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
11. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 Earlier this year in ... Sherley, director of the Adult Stem Cell Technology Center, ... overlooked and under appreciated unique property of adult tissue ... Stem Cells: Misunderstood in the Past, Important for the ... participants. He gave the address at the 4th ...
(Date:12/24/2014)... 23, 2014 The report ... as its definition, classification, application and industry ... manufacturing process, and product cost structure. Production ... The analysis also covers upstream raw materials, ... development trend and proposals. In the end, ...
(Date:12/24/2014)... 2014 China Biologic Products, Inc. (NASDAQ: ... fully integrated plasma-based biopharmaceutical company in ... subsidiary, Shandong Taibang Biological Products Co. Ltd., has ... China Food and Drug Administration (the "CFDA") for ... disclosed in the Company,s public filings, the CFDA ...
(Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) will be presenting ... on Wednesday, June 11, 2008 at 1:20,p.m. PT. Daniel ... will be providing a corporate overview., The live ... be made,available following the event. The Web cast and ...
... Sidec has of today introduced,a new version of ... the analysis of therapeutic antibodies and,drug targets in ... Protein Tomography(TM) uses regularization theory to create ... microscope images. The enhanced Protein,Tomography(TM) method is developed ...
... PRXL ) announced today it will be presenting ... The Ritz Carlton,- Laguna Niguel in Dana Point, California. ... be making a formal presentation,on PAREXEL at 4:40 p.m. ... webcast of this presentation will be available under the,"Upcoming ...
Cached Biology Technology:PAREXEL International to Present at Goldman Sachs 29th Annual Global Healthcare Conference 2
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... a progressive degenerative disease affecting a person,s ability to ... as a tremor in a finger will eventually lead ... inability to walk without assistance. Since the 1950s research ... of the chemical dopamine in their brains, which is ...
... April 23, 2013  According to ... Market (2013 - 2018): by Technology (2D, 3D, Ultrasonic, IR, Capacitive); Product ... , China , Japan ... & Oceania)", is expected to reach $4.18 billion by 2018 ...
... 22, 2013) The current special issue of ... Academy of Inventors ( https://www.cognizantcommunication.com/component/content/article/636 ), devoted to studies ... a wide range of topics, from new technologies to ... human microbiome. "This special issue of ...
Cached Biology News:New research examines connection between inflammatory stimulus and Parkinson's disease 2New research examines connection between inflammatory stimulus and Parkinson's disease 3Asia-Pacific Gesture Recognition & Touchless Sensing Market Worth $4.18 Billion by 2018 2Asia-Pacific Gesture Recognition & Touchless Sensing Market Worth $4.18 Billion by 2018 3Asia-Pacific Gesture Recognition & Touchless Sensing Market Worth $4.18 Billion by 2018 4Technology transforms health care 2Technology transforms health care 3
Porcine TNF-alpha/TNFSF1A ELISpot Development Module...
5-bromo-4-chloro-3-indolyl b -D-galactopyranoside (X-Gal)...
... Western Blot Analysis Kit is an ... developed by Biochain. It detects protein ... or yoctomole (10 -24 M) ... parts: Millennium Enhancer, protein interaction system ...
... universal bioinformatics software that has changed the ... modular design of BioNumerics allows for integration ... of data employed for the characterization of ... 2-D protein gels, HPLC, VNTR, MLST, SNP, ...
Biology Products: